{"id":"NCT02284516","sponsor":"Shire","briefTitle":"A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease and History of Recent Artificial Tear Use","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-06","primaryCompletion":"2015-10-05","completion":"2015-10-05","firstPosted":"2014-11-06","resultsPosted":"2017-03-15","lastUpdate":"2021-06-11"},"enrollment":711,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Disease"],"interventions":[{"type":"DRUG","name":"Lifitegrast","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lifitegrast","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Evaluate the efficacy and safety of Lifitegrast in subjects with dry eye disease and a recent history of artificial tear use.","primaryOutcome":{"measure":"Change From Baseline in Patient-Reported Eye Dryness Score to Day 84","timeFrame":"Baseline to Day 84","effectByArm":[{"arm":"Placebo","deltaMin":69,"sd":17.08},{"arm":"Lifitegrast","deltaMin":68.3,"sd":16.88}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.0007"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":41,"countries":["United States"]},"refs":{"pmids":["34617974","28079022"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":354},"commonTop":["Instillation site irritation","Instillation site reaction","Dysgeusia"]}}